Publikationenliste Prof. Dr. med. Beat Thürlimann

2016

Do all patients with advanced HER2 positive breast cancer need upfront-choemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99.

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00
J Clin Oncol. 2016 Oct 1;34(28):3400-8

Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence

Warschkow R, Cerny T, Schmied BM, Güller U, Thuerlimann B, Joerger M
A population-based analysis of secondary malignancies in breast cancer patients receiving breast reconstruction
Br J Cancer. 2016 Jun 28;115(1):80-4

Warschkow R, Güller U, Tarantino I, Cerny T, Schmied BM, Thuerlimann B, Joerger M
Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer: A Propensity-adjusted, Population-based SEER Trend Analysis

Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V
J Clin Oncol. 2016 Mar 20;34(9):927-35

Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel

Toi M, Ohno S, Saeki T, Nakamura S, Thürlimann B
For choosing axillary treatment, and adjuvant hormonal treatment

Crombag MR, Joerger M, Thürlimann B, Schellens JH, Beijnen JH, Huitema AD
Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer
2015

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer
Breast Cancer Res Treat. 2015 Dec; 154(3): 543-555

Huober J, Thürlimann B
Survival and Bevacizumab in Early Breast Cancer: Time to Reconsider?

Adjuvant bisphosphate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
Lancet. 2015 Oct 3;386(10001):1353-61

Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial
Ann Oncol 26:2442-2449, 2015

Peters S, von Moos R, Thurlimann B
Ist die Verordnung einer Therapie von 150’000 CHF vertretbar?
Swiss Medical Forum (43) 2015: 1005-10

Guidelines for time-to-event end points definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Herrmann C, Ess S, Thürlimann B, Probst-Hensch N, Vounatsou P
40 years of progress in female cancer death risk: a Bayesian spatio-temporal mapping analysis in Switzerland
BMC Cancer. 2015 Oct 9;15(1):666

Senn HJ, Thürlimann B, Gnant M

Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
J Clin Oncol. 2015 Sep 1;33(25):2772-9

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
Lancet. 2015 Oct 3;386(10001):1341-52

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
Lancet. 2015 Oct 3;386(10001):1353-61

**Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel members**
Tailoring therapies - improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
Breast Cancer Res Treat. 2015 Jun;151(2):373-84

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
Ann Oncol. 2015 May;26(5):873-879

**Varga Z, Cassoly E, Li Q, Oehlschlegel C, Tapia C, Lehr HA, Klingbiel D, Thürlimann B, Ruhstaller T**
Standardization for Ki-67 Assessment in Moderately Differentiated Breast Cancer. A Retrospective Analysis of the SAKK 28/12 Study
PLoS One. 2015 Apr 17;10(4)

**2014**

**Rageth C, Thürlimann B, Dupont V, Garzoli E**
A view from the Swiss Society of Senology
SMB Mammography Screening Recommendations: Concerns shared – Conclusions wrong
Schweizerische Ärztezeitung 2014;95: 36

**Knauer M, Thürlimann B**
Adjuvant bisphosphonates in breast cancer treatment

Huober J, Thürlimann B
Bone targeted therapy in breast cancer - an old concept but still much to do

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
Lancet. 2014 Jun 21;383(9935):2127-35
Erratum in: Lancet. 2014 Nov 22;384(9957):1848

Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study

Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08)
Breast. 2014 Jun;23(3):244-9

Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.

Ursula Hasler-Strub, Thomas Ruhestaller, Beat Thürlimann
“Survivorship program”: Beratung nach Brustkrebs erkrankung – ein Projektbericht des Brustzentrums St. Gallen
Schweizer Krebsbulletin Nr 4/2014

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.

Symptoms of endocrine treatment and outcome in the BIG 1-98 study
Breast Cancer Res Treat. 2014 Jan;143(1):159-69

2013

Treatment of breast cancer in the elderly: a prospective, population-based Swiss study

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel members
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Ann Oncol. 2013 Sep;24(9):2206-23

Zaman K, Thuerlimann B, Aebi S
Optimal Sequence of Tamoxifen and Aromatase Inhibitors to Prevent Bone Loss
J Clin Oncol. 2013 Sep 20;31(27):3440-1

Templeton AJ, Thürlimann B, Baumann M, Mark M, Stoll S, Schwizer M, Dietrich D, Ruhstaller T
Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors

Joerger M, Thürlimann B
Chemotherapy regimens in early breast cancer: major controversies and future outlook
Expert Rev Anticancer Ther. 2013 Feb;13(2):165-78

Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial
Ann Oncol. 2013 May;24(5):1203-11

2012

Thomas Beck, Matthias W. Beckmann, Kay Friedrichs, Beat Thürlimann, Patrik Weder
Zukunft der Versorgungsstrukturen beim primären Mammakarzinom
Breast Care 2012;7:496–500

Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial
J Clin Oncol. 2012 Nov 10;30(32):3967-75

Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report

Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials
Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
Br J Cancer. 2012 May 8;106(10):1618-25

A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer
Swiss Med Wkly. 2012 Apr 11;142:w13571

A Population-Based Study on the Implementation of Treatment Recommendations for Chemotherapy in Early Breast Cancer

Trastuzumab Treatment beyond Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss Breast Cancer Centers
Oncology. 2011;81(3-4):160-6

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials
Lancet. 2011 Nov 12;378(9804):1707-16

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8-1 years median follow-up
Lancet Oncol. 2011 Nov;12(12):1101-8

Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)
Ann Oncol 2012 Jun;23(6):1474-81

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause


Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
Lancet. 2011 Aug 27;378(9793):771-84


Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03)
Endocr Relat Cancer 2011 Mar 9;18(2):257-64

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

Mark M, Thürlimann B

Fatal pneumonitis after treatment with pegylated liposomal doxorubicin in a patient with metastatic breast cancer in complete remission
Med Oncol 2011 Jun 12 [Epub ahead of print]

Regan MM, Price KN, Glibbie-Hurder A, Thürlimann B, Gelber RD; for the International Breast Cancer Study Group and BIG 1-98 Collaborative Group

Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
Breast Cancer Res 2011 May 26;13(3):209

Bolla D, Wiedemann N, Oehlschlegel C, Schöning A, Stickel J, Thürlimann PB, Hornung R

Pseudoangiomatous stromal hyperplasia of breast in man: a case report
Breast J. 2011 May;17(3):311-2


Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial


Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
J Clin Oncol. 2011 Mar 20;29(9):1117-24

Cognitive function in postmenopausal breast cancer patients one year after completing
adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
Breast Cancer Res Treat. 2011 Feb;126(1):221-6

Joerger M, Thürlimann B, Huober J
Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant
treatment?

2010

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Correa C, McGale P, Taylor C,
Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast
J Natl Cancer Inst Monogr. 2010;(41):162-77

Thürlimann B
Commentary from the viewpoint of an advocate. “Breast cancer mortality in organized
mammography screening in Denmark—a comparative Study”

Mouridsen HT, Lønning P, Beckmann MW, Blackwell K, Doughty J, Gligorov J, Llombart-
Cussac A, Robidoux A, Thürlimann B, Gnant M
Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in
postmenopausal breast cancer

Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes
Onkologie. 2010;33(8-9):447-50

Brauchli P, Thürlimann B, Crowe SN, Herrmann R
What is the value of the 21-gene recurrence score?
J Clin Oncol. 2010 Nov 10;28(32):e671-2; author reply 673-4

Thürlimann B
Predictors of state-of-the-art management of early breast cancer in Switzerland

Joerger M, Templeton A, Köberle D, Engler H, Riesen WF, Thürlimann B
Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant
osteolytic bone disease on bisphosphonates

Joerger M, Riesen WF, Thürlimann B
Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-
ductal breast cancer

Hess D, Hawle H, Müller A, Thürlimann B
Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to
Previous Endocrine Therapies in a Patient with Advanced Breast Cancer
Case Rep Oncol 2010;3:131-136

The Scientific Board, Harbeck N, von Minckwitz G, Thürlimann B
Bisphosphonates in adjuvant treatment of early breast cancer
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial
Breast 2010;19(5):388-395

Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue
BMC Cancer 2010;10(1):37

Huober J, Schoch O, Templeton A, Spirig C, Thürlimann B
Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer
Chemotherapy 2010;56(1):69-70

Geographic variation in breast cancer care in Switzerland
Cancer Epidemiol 2010;34(2):116-121

Adjuvant!((c)) Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer

Huober J, Thürlimann B
Bone targeted therapy in breast cancer: present and future
Crit Rev Oncol Hematol 2010;74(1):7-10

2009

Huober J, Thürlimann B
The role of combination chemotherapy in the treatment of patients with metastatic breast cancer
Breast Care 2009;4:367-372

Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: An outcome research study
Oncology 2009;76:142-148

Is chemotherapy necessary for premenopausal women with low-risk node-positive, endocrine responsive breast cancer 10-year update of International Breast Cancer Study Group Trial 11-93
Breast Cancer Res Treat 2009;113(1):137-44

Huober J, Thürlimann B
Adjuvant! When the new world meets the old world
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ and panel members
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93

Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century

Giobbie-Hurder A, Price KN, Gelber RD; International Breast Cancer Study Group and BIG 1-98 Collaborative Group
Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer
Clin Trials 2009;6(3):272-87

Markus Joerger, Beat Thürlimann
Update of the BIG 1-98 Trial: Where do we stand?
The Breast 2009;18:78-82

Biganzoli L, Bonnefoi H, Cardoso F, Coleman R, Thürlimann B
ASCO 2009: What's New in Breast Cancer Therapy?
Breast Care (Basel) 2009;4(4):268-271

2008

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 (BIG 1-98) comparing adjuvant tamoxifen with letrozole
J Clin Oncol 2008;26:5569-5575


Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer
Ann Oncol 2008;19:1393-1401


Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial


Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double blind, double-crossover study.
Brit J Cancer 2008;98:300-308


Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
Ann Oncol 2008;19:1231-1241


Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group Clinical Trials
J Clin Oncol 2008;26:3006-3014


Pegylated liposomal Doxorubicin-associated hand-foot syndrome: recommendation of an international panel of experts
Eur J Cancer 2008;44:782-790


Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

Quality of life und quality-adjusted survival (Q-TWIST) in patients receiving dose-intensive or standard dose chemotherapy for high risk primary breast cancer
Brit J Cancer 2008;98:25-33

Strasser F, Demmer R, Böhme C, Schmitz S-F, Thuerlimann B, Cerny T, Gillessen S
Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: A randomized, placebo-controlled, double-blind study
The Oncologist 2008;13:337-346

Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel

Coates A, Mouridsen H, Thürlimann B, Big 1-98 Collaborative Group
Inappropriate ATAC on tamoxifen

Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors; International Breast Cancer Study Group
J Clin Oncol 2008;26(9):1404-10

Renal safety profiles of inbandronate 6 mg infused over 15 and 60 min: a randomized open-label study
Ann Oncol 2008;19(7):1266-70

2007

Capecitabine and vinorelbin as first-line treatment in elderly patients (≥65 years) with metastatic breast cancer
Oncology 2007, 73: 228-237

Pegylated liposomal Doxorubicin (Caelyx®) in Metastatic Breast Cancer: a Community-Based Observation Study
Oncology 2007, 72: 147-151

Thürlimann B, Köberle D, Senn HJ
Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: Past, present and future recommendations
Eur J Cancer 2007, 46: 46-52

Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)
Ann Oncol 2007, 18: 64-69

Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine responsive early breast cancer. Update of study BIG 1-98

Seeholzer N, Thürlimann B, Köberle D, Hess D, Korte W
Combining chemotherapy and low-molecular-weight heparin for the treatment of advanced breast cancer: results on clinical response, transforming growth factor-beta 1 and fibrin monomer in a phase II study
Blood Coagulation and Fibrinolysis 2007, 18: 415-423

Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ and Panel Members
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
Ann Oncol 2007, 18: 1133-1144

Klaeser B, Wiederkehr O, Köberle D, Müller A, Bubeck B, Thürlimann B
Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography in the pre- and postoperative staging of patients with clinically intermediate or high-risk breast cancer

Prognostic and predictive value of centrally reviewed expression of estrogen and progesteron receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98

The International Breast Cancer Study Group
Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) trials 13-93 and 14-93
Ann Oncol 2007, 18: 1177-1184

The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer

Predictors of early relapse in postmenopausal women with hormone receptor positive breast cancer in the BIG 1-98 trial
CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials

Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes and quality of life in premenopausal patients - the International Breast Cancer Study Group Trial VIII

Ruhstaller T, Thürlimann B, von Moos R, Köberle D
Is surgery still part of local therapy in patients with locally advanced esophageal carcinoma?

Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial
J Clin Oncol, 25(36), 2007

Ruhstaller T, Roe H, Thürlimann B, Nicoll JJ
The multidisciplinary meeting: An indispensable aid to communication between different specialities
Eur J Cancer 2006, 42; 2459-2462

Langenegger T, Wahl P, Schiesser D, Thürlimann B
Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis
Breast Cancer Res Treat 2006, 100: 177-181

Goldhirsch A, Coates AS, Gelber RD, Glick JH, Thürlimann B, Senn HJ
First – select the target: better choice of adjuvant treatments for breast cancer patients
Ann Oncol 2006, 17: 1772-76

2005
Is there really enough evidence to abandon surgery after radiation chemotherapy in esophageal cancer?
J Clin Oncol 2005, 33: 8547-8

Adjuvant endocrine therapy in postmenopausal breast cancer
The Breast 2005, 14: 446-451

Meeting highlights: International expert consensus on the primary therapy of early breast cancer
Ann Oncol 2005, 10: 1569-83

Dose finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first line treatment in advanced breast cancer
Ann Oncol 2005, 16: 1609-1617

Current concepts of treatment strategies in metastatic ovarian cancer
Oncology 2005, 68: 293-298

Site of primary tumor has a prognostic role in operable breast cancer: the International Breast Cancer Study Group experience
J Clin Oncol 2005, 23: 1390-1400

Prognostic value of extracapsular tumor spread for locoregional control in premenopausal node-positive breast cancer patients treated with classical CMF: long-term observations from IBCSG Trial VI

Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: Role of endocrine responsiveness of the tumor

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

2004
Hess D, Thürlimann B, Pagani O, Aebi S, Rauch D, Ballabeni B, Rufener B, Castiglione-Gertsch M, Goldhirsch A
on behalf of the Swiss Group of Clinical Cancer Research (SAKK)
Capecitabine and vinorelbine in elderly patients (>65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99)
Ann Oncol 2004, 15: 1760-65

on behalf of the International Breast Cancer Study Group (IBCSG)
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience
Ann Oncol 2004, 15: 875-884

Köberle D, Perey L, Thürlimann B
for the Swiss Group of Clinical Cancer Research (SAKK)
Playing the old piano: another tune for endocrine therapy
JNCI 2004, 96, 7: 555-557

for the Swiss Group of Clinical Cancer Research (SAKK)
Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?
Breast Cancer Res Treat 2004, 87: 75-86

for the International Breast Cancer Study Group (IBCSG)
Quantifying trade-offs: Quality of life and quality adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer
Brit J Cancer 2004, 11: 1893-901

for the Swiss Group for Clinical Cancer Research (SAKK)
Anastrozole (“Arimidex”) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95 – a sub-study of the TARGET (Tamoxifen or “Arimidex” Randomized Group Efficacy and Tolerability) trial

Thürlimann B, Müller A, Senn HJ
Management of primary breast cancer: an update
Onkologie 2004, 27: 175-179

2003

Senn HJ, Thürlimann B, Goldhirsch A, Wood WC, Gelber RD, Coates AS
Comments on the St. Gallen Consensus 2003 on the primary therapy of early breast cancer
The Breast 2003, 12: 569-582

Senn HJ, Thürlimann B
The importance of evidence-based international consensus in the primary treatment of breast cancer – a period "must"
The Breast 2003, 12: 349-350

Von Moos R, Thürlimann B
Weekly paclitaxel (Taxol®) with or without trastuzumab (Herceptin®) in adjuvant breast cancer: a community-based observation study
Onkologie 2003, 26: 128-132

Nabholtz JM, Bonneterre J, Buzdar A, Robertson JF, Thürlimann B
Anastrozole (Arimidex®) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results
Eur J Cancer 2003, 39: 1684-1689

Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ
Meeting highlights: updated international expert consensus of the primary therapy of early breast cancer
J Clin Oncol 2003, 21: 3357-3365

Thürlimann B, Robertson JF, Nabholtz JM, Buzdar A, Bonneterre J
Efficacy of tamoxifen following anastrozole (Arimidex®) compared with anastrozole following tamoxifen as first-line treatment breast cancer in postmenopausal women
Eur J Cancer 2003, 39: 2310-2317

Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group (IBCSG) trials I through VII

Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomised trial (SAKK 23-92) comparing tamoxifen to observation
Ann Oncol 2003, 14:1215-21

Aapro M, Thürlimann B, Sessa C, de Pree Ch, Bernhard J, Maibach R
SAKK 90/95: A randomized double-blind trial of the Swiss Group for Clinical Cancer Research (SAKK) to compare the clinical efficacy of granisetron to metoclopramide, both combined to dexamethasone in prophylaxis of chemotherapy induced delayed emesis

2002

Thürlimann B
Anastrozole versus Progestins / tamoxifen
Eur J Cancer 2002, 38: 49–51

Rose C, Boccardo F, Piccard M, Thürlimann BJK, Holli K
Guidelines on endocrine therapy of breast cancer EUSOMA: endocrine therapy in primary breast cancer
Eur J Cancer 2002, 38: 624-27
Vinorelbine in androgen-independent metastatic prostatic carcinoma - a phase II study
Eur J Cancer 2002, 38: 1626-32

for the International Breast Cancer Study Group (IBCSG) and the German Breast Cancer Study Group
Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomized trials investigating 3 versus 6 courses of CMF (cyclophosphamide, methotrexate and 5-fluorouracil)
Brit J Cancer 2002; 86(11): 1705-14

Bernhard J, Maibach R, Thürlimann B, Sessa C, Aapro MS
for the Swiss Group for Clinical Cancer Research (SAKK)
Patient’s estimation of overall treatment burden: why not ask the obvious?

2001

Thürlimann B
International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland
Breast Cancer 2001, 8: 294-297

High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel

for the International Breast Cancer Study Group (IBCSG)
Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer

Köberle D, Thürlimann B
Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer
Expert Rev Anticancer Ther 2001, 1: 89-96

Bonneterre J, Buzdar A, Robertson JFR, Thürlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M, Wilmington DE
Anastrozole (Arimidex®) is superior to tamoxifen as first-line therapy in hormone receptor-positive patients with advanced breast cancer: results of a combined analysis of two similarly designed randomized trials
Cancer 2001, 92: 2247-58

Thürlimann B, Price KN, Goldhirsch A, Gelber RD, Coates AS, Bernhard J, Zahrieh D
for the International Breast Cancer Study Group (IBCSG)
Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal
women with node-positive, endocrine responsive breast cancer? First results of International Breast Cancer Study Group (IBCSG) Trial 11-93
The Breast 2001, 10: 130-38

2000

Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women
Eur J Cancer 2000, 36: 84-85

Anastrozole versus tamoxifen as first line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex® Randomized Group Efficacy and Tolerability (TARGET) study
J Clin Oncol, 2000, 18: 3748-57

Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group.

Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment

Identifying breast cancer patients at high risk for bone metastases
J Clin Oncol 2000; 18: 3925-3935

Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group (IBCSG) Trial VII

Ruhstaller T.W., Thürlimann B
Small-cell lung cancer with brain metastases and survival for more than 15 years despite incomplete therapy
Onkologie 2000; 23: 64-66

Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma
Ann Oncol 2000; 11(12): 183-188
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study
Ann Oncol 2000; 11(8): 985-991

Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors

Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
Lancet 2000; 355(9218): 1869-1874

Gessner U, Köberle D, Thürlimann B, Bacchus L, Horisberger B
Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate
Support Care Cancer 2000; 8(2): 115-122

1999

Sieger D, D‘Addario N, Lorenz U, Bacchi M, Thürlimann B
Dose Escalation of Carboplatin and Cyclophosphamide Supported by GM-CSF in the Treatment of Patients with Advanced Ovarian Cancer (FIGO III and IV) – a Phase I Study
Onkologie 1999; 22(6): 502-506

Köberle D, Bacchus L, Thürlimann B, Senn HJ
Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial
Support Care Cancer 1999; 7(1): 21-27

Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy
J Clin Endocrinol Metab 1999; 84(10): 3445-3450

Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment

Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
J Clin Oncol 1999; 17(6): 1672-1679

Mannhart-Harms M, Diener PA, Thürlimann B, Urscheler R
Papillary Thyroid Carcinoma in an Adult Teratoma in Combination with Mucinous Cystadenoma of the Ovary
Onkologie 1999; 22(3): 222-224
Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
Ann Oncol 1999; 10(5): 539-545

Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients
Support Care Cancer 1999; 7(3): 149-153

1998

Thürlimann B
Hormonal treatment of breast cancer: new developments
Oncology 1998; 55(6): 501-507

Factors affecting baseline quality of life in two international adjuvant breast cancer trials
Br J Cancer 1998; 78(5): 686-693

Engler H, Koebeler D, Thuerlimann B, Senn HJ, Riesen WF
Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease

Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer

Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) trial VI

Lehnert M, Mross K, Schueller J, Thuerlimann B, Kroeger N, Kupper H
Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer
Br J Cancer 1998; 77(5): 1155-1163

Hürny C, van Wegberg B, Bacchi M, Bernhard J, Thürlimann B, Real O, Perey L, Bonnefoi H, Coates A
Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for clinical trials
Br J Cancer 1998; 77(6): 985-991

1997


1996


Thürlimann B, Senn HJ
The changing approach to the treatment of early breast cancer

Engler H, Thürlimann B, Riesen WF
Biochemical markers of bone remodelling
Onkologie 1996; 19: 126-131

International Breast Cancer Study Group
Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients

1995

Dexverapamil to overcome epirubicin resistance in advanced breast cancer
J Cancer Res Clin Oncol 1995; 121 Suppl 3: R3-6


1994

Thürlimann B, Morant R, Jungi WF, Radziwill A
Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study
Support Care Cancer 1994; 2(1): 61-65

First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation

Joss RA, Bacchi M, Buser K, Kirchner V, Neuenschwander H, Orth B, Aapro MS, Thürlimann B
Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive und previously treated patients
Ann Oncol 1994; 5(3): 253-258

1993

Radziwill AJ, Thürlimann B, Jungi WF
Improvement of Palliation in Patients with Osteolytic Bone Disease and Unsatisfactory Pain Control after Pretreatment with Disodium Pamidronate: An Intrapatient Dose Escalation Study
Onkologie 1993; 16: 174-177

Thürlimann B, Osterwalder B, Jungi WF, Morant R, Schmid L, Senn HJ
FOM: An Effective Non-Cisplatin-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer with Low Toxicity
1992

Thürlimann B, Bachmann I
Effective prevention of chemotherapy-induced phlebitis by low-dose heparin: a prospective randomised trial

Thürlimann B, Waldberger R, Senn HJ, Thiébaud D
Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial

1990

Thürlimann B, Senn HJ
Anthracycline-carboplatin combination in metastatic breast cancer

1987

Thürlimann B, Varini M, Senn HJ
Trilostane in advanced pretreated breast cancer: a phase II trial of the Swiss Group for Clinical Cancer Research (SAKK)
TumorDiagnostik & Therapie 1990; 11: 5-7

1985

Zur Bedeutung der Schilddrüsenhormonbestimmung für die Diagnose der Hyperthyreose - eine deutliche Verbesserung der ärztlichen Beurteilung durch die Anwendung entscheidungstheoretischer Erkenntnisse
Nuklearmedizin 1985; 24(3): 127-134

Thürlimann BJ, Falkson G
Gonadotrophin-releasing hormone analogue agonists - a new approach in advanced prostatic cancer